Table 3. Pharmacokinetic parameters of TPN729MA in rats and dogs after intravenous bolus and oral administration. Data are presented as the arithmetic mean±standard deviation except for Tmax as median (range).
| Species | Dosing route | Dose mg/kg | Tmax (h) | Cmax (ng/mL) | AUC0-∞ (ng·h/mL) | t1/2 (h) | CL (mL·min−1·kg−1) | Vss (L/kg) | F (%) |
|---|---|---|---|---|---|---|---|---|---|
| Rat | Iv (n=6) | 1 | 196±16 | 3.36±1.96 | 69.7±5.7 | 7.35±0.75 | |||
| Oral (n6) | 1 | 1.0 (0.33-4.0) | 3.58±2.71 | 20.5±7.8 | 6.73±2.88 | 10.4 | |||
| Oral (n6) | 3 | 0.67 (0.17-4.0) | 10.7±5.6 | 56.1±11.1 | 4.81±1.65 | 9.5 | |||
| Oral (n6) | 10 | 0.67 (0.33-2.0) | 44.3±28.4 | 207±46 | 3.55±0.87 | 10.5 | |||
| Dog | Iv (n3) | 3 | 1550±17 | 3.39±0.21 | 26.3±5.0 | 6.48±0.56 | |||
| Oral (n6) | 3 | 1.3 (0.25-1.5) | 103±23 | 525±153 | 3.96±0.48 | 34.5 | |||
| Oral (n6) | 9 | 1.5 (1.0-2.0) | 505±229 | 2763±1061 | 3.28±0.34 | 59.4 |